Welcome to our dedicated page for Rigel Pharmaceuticals SEC filings (Ticker: RIGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rigel Pharmaceuticals' SEC filings document the regulatory record of a Delaware biotechnology company with common stock listed on Nasdaq under RIGL. Its 8-K reports frequently furnish operating results, product revenue trends, collaboration revenue and business updates tied to TAVALISSE, GAVRETO, REZLIDHIA and development programs such as R289.
The filings also cover material agreements, license and collaboration disclosures, capital-structure information for common stock, and governance matters. Proxy materials describe shareholder voting items, board matters, executive compensation and equity awards, while material-event filings record changes affecting agreements, financial reporting and corporate governance.
MILLER MICHAEL PATRICK reported acquisition or exercise transactions in this Form 4 filing.
RIGEL PHARMACEUTICALS INC director Michael Patrick Miller reported an equity grant of 5,750 shares of Common Stock via Restricted Stock Units. The award has a grant price of $0.00 per share because it is a compensation grant, not a market purchase.
According to the footnote, these Restricted Stock Units will fully vest on the date prior to the company’s next Annual Meeting, as long as Miller continues serving on the Board of Directors. After this grant, he holds 5,937 shares of Common Stock directly.
LAPOINTE ANTHONY GREGG reported acquisition or exercise transactions in this Form 4 filing.
RIGEL PHARMACEUTICALS INC director Anthony Gregg Lapointe reported an equity compensation grant of 5,750 shares of Common Stock, recorded at a price of $0.00 per share. These shares are tied to a Restricted Stock Unit award that will fully vest on the date prior to the company’s next Annual Meeting, if he continues serving on the Board of Directors. Following this award, Lapointe’s reported direct holdings total 18,250 shares of Common Stock.
RIGEL PHARMACEUTICALS INC director Alison L. Hannah received an equity award in the form of Restricted Stock Units. The filing shows a grant of 5,750 shares of Common Stock at a price of $0.00 per share, reflecting a compensation-related award rather than a market purchase.
These shares are to be acquired upon vesting of the Restricted Stock Unit award. According to the terms, the units will fully vest on the date prior to the company’s next Annual Meeting, as long as she continues to serve on the Board of Directors. After this grant, her direct Common Stock holdings reported in this filing total 16,375 shares.
Rigel Pharmaceuticals director Mark W. Frohlich was granted 5,750 restricted stock units of common stock at no cost. These units will be acquired upon vesting and are scheduled to fully vest on the date prior to the company’s next annual meeting, subject to his continued service on the board. Following this equity award, Frohlich beneficially owns 7,000 shares of Rigel’s common stock.
Ali-Jackson Kamil reported acquisition or exercise transactions in this Form 4 filing.
RIGEL PHARMACEUTICALS INC director Kamil Ali-Jackson received a stock grant tied to board service. The Form 4 shows an award of 5,750 shares of Common Stock at no cash cost, delivered as Restricted Stock Units. These units will fully vest on the date prior to the company’s next Annual Meeting, as long as the director continues serving on the Board. After this grant, the director holds 15,125 shares of Common Stock directly.
Rigel Pharmaceuticals reports that Armistice Capital, LLC and Steven Boyd jointly hold 1,280,000 shares of Common Stock, representing 6.93% of the class as of 03/31/2026. The filing states Armistice Capital exercises shared voting and dispositive power over those shares under an Investment Management Agreement, and the Master Fund is the direct holder. The statement is a Schedule 13G joint filing signed on 05/15/2026.
Rigel Pharmaceuticals has entered into an exclusive, royalty-bearing worldwide license agreement with Arvinas entities and Pfizer to develop, manufacture and commercialize VEPPANU (vepdegestrant) and related products. VEPPANU is approved in the United States for certain ER+, HER2‑negative, ESR1‑mutated advanced or metastatic breast cancer.
Rigel will pay an upfront $70 million, up to $15 million tied to transition activities, and up to $320 million in potential regulatory and sales milestone payments, plus tiered royalties from the mid‑teens to mid‑twenties on net sales. Rigel will lead global development and commercialization, while reimbursing specified ongoing development costs up to $40 million. The agreement becomes effective after expiration or termination of the applicable Hart‑Scott‑Rodino antitrust waiting period.
Rigel Pharmaceuticals, Inc. ownership disclosure: Soleus Capital Master Fund, L.P. and affiliated entities report beneficial ownership of 968,108 shares of Rigel common stock, representing 5.2% of the class. The percentage is calculated using 18,502,080 shares outstanding as of April 30, 2026 per Rigel's Form 10-Q cover.
The filing attributes the shares to the Master Fund and describes the ownership/management chain (Soleus Capital, LLC; Soleus Capital Group, LLC; Soleus Capital Management, L.P.; Soleus GP, LLC) and a disclaimer of beneficial ownership by related entities, signed by Guy Levy.
Rigel Pharmaceuticals reported first quarter 2026 total revenues of $58.8 million, driven by $54.9 million in net product sales and $3.9 million in contract revenues from collaborations. Net product sales rose 26% year over year, reflecting growth across its hematology-oncology portfolio.
TAVALISSE net product sales were $37.3 million, up 31%, GAVRETO reached $9.6 million, up 7%, and REZLIDHIA generated $8.0 million, up 31% versus the same period in 2025. Rigel posted net income of $8.7 million, or $0.47 basic and $0.44 diluted per share, compared with $11.4 million a year earlier, as total costs and expenses increased to $46.9 million on higher R&D and commercial spending.
Cash, cash equivalents and short-term investments were $146.7 million as of March 31, 2026. The company reaffirmed its 2026 outlook for total revenues of approximately $275–$290 million, including net product sales of $255–$265 million and contract revenues of $20–$25 million, and continues to anticipate positive full-year net income while funding ongoing clinical programs such as R289.
Rigel Pharmaceuticals reported a profitable first quarter of 2026 with higher product sales and continued investment in its pipeline. Total revenues were $58.8 million, up from $53.3 million a year earlier, driven by net product sales of $54.9 million. TAVALISSE, REZLIDHIA and GAVRETO net sales were $37.3 million, $8.0 million and $9.6 million, respectively, each growing versus 2025.
Net income was $8.7 million compared with $11.4 million, as operating expenses and a higher $3.0 million tax provision offset revenue gains. Diluted EPS was $0.44. Cash, cash equivalents and short‑term investments totaled $146.7 million, with $45.0 million of term debt outstanding at March 31, 2026 and operating cash flow of $2.7 million.
Rigel highlighted progress in its R289 Phase 1b study and broader olutasidenib collaborations in hematologic cancers and high‑grade glioma. The company received notice in April 2026 that Eli Lilly will terminate their global RIPK1 collaboration effective June 15, 2026, after which Rigel expects to regain full rights to the compounds. In May 2026 Rigel refinanced its term loan into a new $40.0 million revolving credit facility with MidCap.